ABVC BioPharma, Inc.
ABVCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ABVC BioPharma, Inc. focuses on Biotechnology services and products. ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. At a $32.0M market cap, ABVC BioPharma, Inc. ranks as a micro-cap company within healthcare. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Market Cap
$32.0M
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
-2.80
EPS (TTM)
$-0.40
EPS (Fwd)
$-0.44
ROE
-87.8%
ROA
-29.0%
Cash
$202,509
Total Debt
$2.7M
Free CF
$1.2M
52W Change
-59.1%
Annual Financials
Cash vs Debt
Where ABVC stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ABVC finished 13.55% below its 150-day moving average ($1.55) and 29.10% below its 200-day moving average ($1.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABVC overbought or oversold?
At the July 15, 2026 close, ABVC's RSI(14) was 51.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $203K in cash, though total debt stands at $2.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $1.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -87.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $970K (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.54 suggests ABVC is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing ABVC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.